4//SEC Filing
Vazquez Martin 4
Accession 0001484612-23-000026
CIK 0001484612other
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 6:15 PM ET
Size
23.5 KB
Accession
0001484612-23-000026
Insider Transaction Report
Form 4
Vazquez Martin
Chief Operating Officer
Transactions
- Sale
Common Stock
2023-02-02$30.00/sh−6,500$195,000→ 104,435 total - Exercise/Conversion
Common Stock
2023-02-02$3.88/sh+6,500$25,220→ 110,935 total - Sale
Common Stock
2023-02-02$30.00/sh−6,500$195,000→ 104,435 total - Exercise/Conversion
Common Stock
2023-02-01$3.88/sh+5,000$19,400→ 109,435 total - Exercise/Conversion
Common Stock
2023-02-02$3.88/sh+6,500$25,220→ 110,935 total - Sale
Common Stock
2023-02-01$27.91/sh−5,000$139,554→ 104,435 total - Exercise/Conversion
Common Stock
2023-02-02$3.88/sh+6,500$25,220→ 110,935 total - Sale
Common Stock
2023-02-02$30.00/sh−6,500$195,000→ 104,435 total - Exercise/Conversion
Performance Options (right to buy)
2023-02-01−5,000→ 68,007 totalExercise: $3.88Exp: 2027-12-19→ Common Stock (5,000 underlying) - Exercise/Conversion
Performance Options (right to buy)
2023-02-02−6,500→ 61,507 totalExercise: $3.88Exp: 2027-12-19→ Common Stock (6,500 underlying) - Exercise/Conversion
Performance Options (right to buy)
2023-02-02−6,500→ 55,007 totalExercise: $3.88Exp: 2027-12-19→ Common Stock (6,500 underlying) - Exercise/Conversion
Performance Options (right to buy)
2023-02-02−6,500→ 48,507 totalExercise: $3.88Exp: 2027-12-19→ Common Stock (6,500 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2022.
- [F2]The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from: $27.00 - $27.99 - 3,640 shares; $28.00 - $28.99 - 1,360 shares. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold within the range set forth in this footnote.
- [F3]In March 2021, following the expiration of the lock-up period in connection with our initial public offering, the applicable performance and market-based vesting conditions were met and the shares underlying this stock option award became fully vested.
- [F4]In March 2021, following the expiration of the lock-up period in connection with our initial public offering, the applicable performance and market-based vesting conditions were met and the shares underlying this stock option award became fully vested.
Documents
Issuer
Outset Medical, Inc.
CIK 0001484612
Entity typeother
Related Parties
1- filerCIK 0001823380
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 6:15 PM ET
- Size
- 23.5 KB